Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced the appointment of Kirsten Castillo and Prabhavathi Fernandes, Ph.D. to its board of directors.
April 7, 2020
· 4 min read